Combination of ICSs and LABAs should be used in the management of patients with COPD - the con argument.
Road
Jeremy
J
University of British Columbia, Vancouver. jroad@interchange.ubc.ca
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use*; D058666:Adrenergic beta-2 Receptor Agonists; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D018343:Receptors, Adrenergic, beta-2 / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D058666:Adrenergic beta-2 Receptor Agonists; D003692:Delayed-Action Preparations; D018343:Receptors, Adrenergic, beta-2